Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Arbutus Biopharma Corp (ABUS) stock profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate that, in a Phase Ia/Ib clinical trial, was targeted to hepatocytes to inhibit viral replication and reduce various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer that leads to the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken the patient's HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc., Gritstone Oncology, Inc., Alnylam Pharmaceuticals, Inc., Qilu Pharmaceuticals Co., Ltd., Assembly Biosciences, Inc., Acuitas Therapeutics, Inc., and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. It is headquartered in Warminster, Pennsylvania.

Key facts

SymbolABUS
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOLindsay Androski
Employees19
HeadquartersWarminster, PA, US
IPO2007-07-26
Websitewww.arbutusbio.com

Explore ABUS on Vantafin

  • Arbutus Biopharma Corp Overview
  • Arbutus Biopharma Corp Financials
  • Arbutus Biopharma Corp News
  • Arbutus Biopharma Corp Events
  • Arbutus Biopharma Corp SEC filings
  • Arbutus Biopharma Corp Insider transactions
  • Arbutus Biopharma Corp Transcripts

Frequently asked questions

What does Arbutus Biopharma Corp (ABUS) do?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate that, in a Phase Ia/Ib clinical trial, was targeted to hepatocytes to inhibit viral replication and reduce various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer that leads to the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken the patient's HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc., Gritstone Oncology, Inc., Alnylam Pharmaceuticals, Inc., Qilu Pharmaceuticals Co., Ltd., Assembly Biosciences, Inc., Acuitas Therapeutics, Inc., and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. It is headquartered in Warminster, Pennsylvania.
Where is ABUS stock listed?
Arbutus Biopharma Corp trades under the ticker ABUS on NASDAQ.
How can I research ABUS's financials and filings?
Vantafin provides Arbutus Biopharma Corp's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ABUS profile.